CA2873963C - Carboline and carbazole based imaging agents for detecting neurological dysfunction - Google Patents
Carboline and carbazole based imaging agents for detecting neurological dysfunction Download PDFInfo
- Publication number
- CA2873963C CA2873963C CA2873963A CA2873963A CA2873963C CA 2873963 C CA2873963 C CA 2873963C CA 2873963 A CA2873963 A CA 2873963A CA 2873963 A CA2873963 A CA 2873963A CA 2873963 C CA2873963 C CA 2873963C
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- ethoxy
- reaction
- optionally replaced
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/477,095 | 2012-05-22 | ||
| US13/477,095 US8932557B2 (en) | 2008-02-14 | 2012-05-22 | Imaging agents for detecting neurological dysfunction |
| PCT/US2012/061912 WO2013176698A1 (en) | 2012-05-22 | 2012-10-25 | Carboline and carbazole based imaging agents for detecting neurological dysfunction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2873963A1 CA2873963A1 (en) | 2013-11-28 |
| CA2873963C true CA2873963C (en) | 2017-04-11 |
Family
ID=47146722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2873963A Active CA2873963C (en) | 2012-05-22 | 2012-10-25 | Carboline and carbazole based imaging agents for detecting neurological dysfunction |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2852572B1 (https=) |
| JP (1) | JP5976206B2 (https=) |
| KR (1) | KR101609504B1 (https=) |
| CN (2) | CN104781234A (https=) |
| AU (1) | AU2012381042B2 (https=) |
| CA (1) | CA2873963C (https=) |
| CO (1) | CO7131359A2 (https=) |
| ES (1) | ES2792830T3 (https=) |
| WO (1) | WO2013176698A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015110263A1 (en) * | 2014-01-21 | 2015-07-30 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins |
| JP6762233B2 (ja) * | 2014-04-22 | 2020-09-30 | ウニヴェルシテ ド モントリオールＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｍｏｎｔｒｅａｌ | 化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用 |
| HUE053939T2 (hu) | 2014-05-13 | 2021-08-30 | Hoffmann La Roche | Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk |
| EA036518B1 (ru) * | 2015-02-02 | 2020-11-18 | Юсб Байофарма Спрл | Производные 9h-пирролодипиридина |
| JP6609866B2 (ja) * | 2015-03-04 | 2019-11-27 | 国立大学法人京都大学 | 放射性ヨウ素標識ピリド［１，２−ａ］ベンゾイミダゾール誘導体化合物 |
| TW201707726A (zh) * | 2015-08-19 | 2017-03-01 | 國立大學法人京都大學 | 放射性鹵素標誌吡啶并［１，２－ａ］苯并咪唑衍生物化合物 |
| CA3003884C (en) | 2015-11-13 | 2020-04-21 | Eli Lilly And Company | Azetidine derivatives for tau imaging |
| KR102472003B1 (ko) | 2016-07-22 | 2022-11-29 | 에이씨 이뮨 에스에이 | 타우 단백질 응집체를 이미징하기 위한 화합물 |
| WO2018015546A1 (en) | 2016-07-22 | 2018-01-25 | Ac Immune S.A. | Compounds for imaging tau protein aggregates |
| WO2018024642A1 (en) | 2016-08-02 | 2018-02-08 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
| WO2018024643A1 (en) | 2016-08-02 | 2018-02-08 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives |
| MX2019005007A (es) * | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| CN109884194A (zh) * | 2017-12-06 | 2019-06-14 | 新疆维吾尔药业有限责任公司 | 一种药用植物的分离方法及其产品和应用 |
| US20210041447A1 (en) | 2018-01-24 | 2021-02-11 | Ac Immune Sa | Azacarboline compounds for the detection of tau aggregates |
| EP3743423A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Gamma-carboline compounds for the detection of tau aggregates |
| CN108409634B (zh) * | 2018-05-10 | 2021-04-27 | 曲阜师范大学 | 咔唑类荧光胺类化合物标记试剂、合成和应用 |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| KR102215255B1 (ko) * | 2019-06-12 | 2021-02-15 | 한국과학기술연구원 | 타우 응집체에 선택적으로 결합하는 형광 탐침자로서 유효한 신규 화합물 및 이의 제조 방법 |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CN116003402B (zh) * | 2021-11-02 | 2025-08-29 | 上海如絮生物科技有限公司 | 一种三环类化合物、其中间体、制备方法和应用 |
| CN114539250B (zh) * | 2022-03-04 | 2023-08-29 | 上海裕兰生物科技有限公司 | 一种阿尔兹海默症PET-tau示踪剂的制备方法 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| KR20250137711A (ko) | 2023-02-02 | 2025-09-18 | 일라이 릴리 앤드 캄파니 | 타우 영상화를 위한 신규 화합물 |
| CN117050070B (zh) * | 2023-07-05 | 2025-10-14 | 湘潭大学 | 一种荧光探针及其制备方法和在Aβ检测中的应用 |
| WO2025155625A1 (en) | 2024-01-16 | 2025-07-24 | Eli Lilly And Company | Novel compounds for tau imaging |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090170882A1 (en) * | 2004-06-30 | 2009-07-02 | Dashyant Dhanak | Methods and compositions |
| FR2885905A1 (fr) * | 2005-05-23 | 2006-11-24 | Trophos Sa | Nouveaux composes chimiques et leurs utilisations comme medicament |
| DE102006062203A1 (de) * | 2006-12-22 | 2008-06-26 | Curacyte Discovery Gmbh | Substituierte 5H-Pyrimido[5,4-b]indole als Induktoren der Apoptose bei B-CLL Zellen |
| WO2008132454A1 (en) * | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines and their use as imaging agents |
| EP2247558B2 (en) * | 2008-02-14 | 2024-07-03 | Eli Lilly and Company | Novel imaging agents for detecting neurological dysfunction |
| JP2011529086A (ja) * | 2008-07-24 | 2011-12-01 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | Ａｄ病変を同定するために有用な造影剤 |
| JP2012051804A (ja) * | 2008-12-26 | 2012-03-15 | Kyoto Univ | Ｅｇ５阻害剤 |
| JP2012521988A (ja) * | 2009-03-23 | 2012-09-20 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経学的障害を検知するためのイメージング剤 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| US10639608B2 (en) * | 2010-04-08 | 2020-05-05 | Siemens Medical Solutions Usa, Inc. | System, device and method for preparing tracers and transferring materials during radiosynthesis |
| JP5585382B2 (ja) * | 2010-10-22 | 2014-09-10 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子、照明装置及び表示装置 |
-
2012
- 2012-10-25 CN CN201280073373.0A patent/CN104781234A/zh active Pending
- 2012-10-25 CA CA2873963A patent/CA2873963C/en active Active
- 2012-10-25 ES ES12783780T patent/ES2792830T3/es active Active
- 2012-10-25 EP EP12783780.5A patent/EP2852572B1/en active Active
- 2012-10-25 CN CN201611136351.0A patent/CN107011342A/zh active Pending
- 2012-10-25 KR KR1020147032388A patent/KR101609504B1/ko active Active
- 2012-10-25 JP JP2015513993A patent/JP5976206B2/ja active Active
- 2012-10-25 WO PCT/US2012/061912 patent/WO2013176698A1/en not_active Ceased
- 2012-10-25 AU AU2012381042A patent/AU2012381042B2/en active Active
-
2014
- 2014-11-20 CO CO14255692A patent/CO7131359A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2852572B1 (en) | 2020-04-01 |
| CA2873963A1 (en) | 2013-11-28 |
| KR20150002854A (ko) | 2015-01-07 |
| CN104781234A (zh) | 2015-07-15 |
| CO7131359A2 (es) | 2014-12-01 |
| AU2012381042B2 (en) | 2015-10-01 |
| EP2852572A1 (en) | 2015-04-01 |
| KR101609504B1 (ko) | 2016-04-05 |
| CN107011342A (zh) | 2017-08-04 |
| JP2015517572A (ja) | 2015-06-22 |
| AU2012381042A1 (en) | 2014-11-20 |
| WO2013176698A1 (en) | 2013-11-28 |
| ES2792830T3 (es) | 2020-11-12 |
| JP5976206B2 (ja) | 2016-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2873963C (en) | Carboline and carbazole based imaging agents for detecting neurological dysfunction | |
| US8932557B2 (en) | Imaging agents for detecting neurological dysfunction | |
| ES2907992T5 (en) | Novel imaging agents for detecting neurological dysfunction | |
| TWI513698B (zh) | 做為ｔａｕ－ｐｅｔ－配位體之二氮雜咔唑衍生物 | |
| BR112020025618A2 (pt) | piridinila e pirazinil-(aza)indolsulfonamidas | |
| CN102448933A (zh) | 作为pbr配体的吲哚衍生物 | |
| JP4467307B2 (ja) | ５−ｈｔ受容体アンタゴニストとしてのピリジルスルホン誘導体 | |
| JP2016517426A (ja) | 置換プリン化合物の合成方法 | |
| CN102574859A (zh) | 作为体内显像剂的[18f]-标记氟马西尼类似物 | |
| JP2012520855A (ja) | インビボイメージング用の放射性標識ピリジニル誘導体 | |
| CN105593210B (zh) | 用于体内成像的咔唑化合物 | |
| JP5744057B2 (ja) | アリールオキシアニリドイメージング剤 | |
| CN102223900A (zh) | 用于多巴胺d2受体的成像配体 | |
| TWI917391B (zh) | 用於亨丁頓(huntingtin)蛋白造影之雜環化合物及造影劑 | |
| TW202604903A (zh) | 作為kras抑制劑的稠合吡啶酮類化合物的製備方法、中間體及其製備方法 | |
| HK1167393B (en) | Tricyclic indole derivates as pbr ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20141021 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240930 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240930 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250924 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250924 |